Abstract
Objectives(1) Describe how the risk of major adverse cardiovascular events (MACE) in individuals with chronic myeloid leukaemia (CML) has evolved; (2) evaluate the risk of MACE associated with the prescription...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have